Chemistry 2C Lab Manual Standard Operating Procedures Spring Quarter 2018
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
AHFS Pharmacologic-Therapeutic Classification System
AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective -
Determination of Iodate in Iodised Salt by Redox Titration
College of Science Determination of Iodate in Iodised Salt by Redox Titration Safety • 0.6 M potassium iodide solution (10 g solid KI made up to 100 mL with distilled water) • 0.5% starch indicator solution Lab coats, safety glasses and enclosed footwear must (see below for preparation) be worn at all times in the laboratory. • 250 mL volumetric flask Introduction • 50 mL pipette (or 20 and 10 mL pipettes) • 250 mL conical flasks New Zealand soil is low in iodine and hence New Zealand food is low in iodine. Until iodised salt was • 10 mL measuring cylinder commonly used (starting in 1924), a large proportion • burette and stand of school children were reported as being affected • distilled water by iodine deficiency – as high as 60% in Canterbury schools, and averaging 20 − 40% overall. In the worst cases this deficiency can lead to disorders such as Method goitre, and impaired physical and mental development. 1. Preparation of 0.002 mol L−1 sodium thiosulfate In earlier times salt was “iodised” by the addition of solution: Accurately weigh about 2.5 g of solid potassium iodide; however, nowadays iodine is more sodium thiosulfate (NaS2O3•5H2O) and dissolve in commonly added in the form of potassium iodate 100 mL of distilled water in a volumetric flask. (This gives a 0.1 mol L−1 solution). Then use a pipette to (KIO3). The Australia New Zealand Food Standards Code specifies that iodised salt must contain: “equivalent to transfer 10 mL of this solution to a 500 mL volumetric no less than 25 mg/kg of iodine; and no more than 65 flask and dilute by adding distilled water up to the mg/kg of iodine”. -
WHO Model List of Essential Medicines
WHO Model List of Essential Medicines 15th list, March 2007 Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html 15th edition Essential Medicines WHO Model List (revised March 2007) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost‐effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost‐effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost‐effectiveness in a variety of settings. The square box symbol () is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Therapeutic equivalence is only indicated on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines. -
United States Patent Office Patented Apr
3,505,222 United States Patent Office Patented Apr. 7, 1970 1. 2 3,505,222 product of a mercaptain with sulfur trioxide. Their metal LUBRICANT COMPOSITIONS salts are represented by the formula: Leonard M. Niebylski, Birmingham, Mich, assignor to O Ethyl Corporation, New York, N.Y., a corporation of Virginia (R-S-S-0--M No Drawing. Filed Mar. 29, 1967, Ser. No. 626,701 5 s (I) Int. C. C10m 5/14, 3/18, 7/36 wherein R is a hydrocarbon radical containing from 1 U.S. C. 252-17 2 Claims to about 30 carbon atoms, M is a metal, and n is the valence of metal M. For example, when M is the monova 0. lent sodium ion, n is 1. ABSTRACT OF THE DISCLOSURE The radical R can be an alkyl, cycloalkyl, aralkyl, The extreme pressure wear properties of base lubri alkaryl, or aryl radical. The radicals may contain other cants including water, hydrocarbons, polyesters, silicones, nonhydrocarbon substituents such as chloro, bromo, iodo, polyethers and halocarbons is enhanced by the addition fluoro, nitro, hydroxyl, nitrile, isocyanate, carboxyl, car of a synergistic mixture of a thiosulfate compound and 15 bonyl, and the like. a lead compound. The useful metals are all those capable of forming Bunte salts. Preferred metals are those previously listed as suitable for forming metal thiosulfates. Of these, the Background more preferred metals are sodium and lead, and lead is 20 the most preferred metal in the Bunte salts. This invention relates to improved lubricant composi Examples of useful Bunte salts include: tions. -
Sodium Nitrite and Sodium Thiosulfate
PATIENT & CAREGIVER EDUCATION Sodium Nitrite and Sodium Thiosulfate This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Nithiodote Warning This drug may cause low blood pressure and a red blood cell problem called methemoglobinemia. These may be life-threatening. This drug is only for use when cyanide poisoning is life-threatening. This drug must be used with care if it is not known if cyanide poisoning has happened. Talk with the doctor. Tell the doctor if your child has inhaled a lot of smoke or if your child has any of these health problems: Anemia, heart problems, lack of a certain enzyme called congenital methemoglobin reductase deficiency, or lung problems. What is this drug used for? It is used to treat cyanide poisoning. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. Sodium Nitrite and Sodium Thiosulfate 1/6 If your child is breast-feeding a baby: Be sure your child does not breast-feed a baby while taking this drug. This drug may interact with other drugs or health problems. Tell the doctor and pharmacist about all of your child’s drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe to give this drug with all of your child’s other drugs and health problems. -
Assessing the in Situ Efficacy of Tea Tree Oil As a Topical Antiseptic
Novasel Australia Pty Ltd Assessing the in situ efficacy of tea tree oil as a topical antiseptic A report for the Rural Industries Research and Development Corporation by S. Messager, K.A. Hammer & T.V. Riley August 2005 RIRDC Publication No 05/113 RIRDC Project No UWA-72A © 2005 Rural Industries Research and Development Corporation. All rights reserved. ISBN 1 74151 176 3 ISSN 1440-6845 Assessing the in situ efficacy of tea tree oil as a topical antiseptic Publication No. 05/113 Project No. UWA-72A The information contained in this publication is intended for general use to assist public knowledge and discussion and to help improve the development of sustainable industries. The information should not be relied upon for the purpose of a particular matter. Specialist and/or appropriate legal advice should be obtained before any action or decision is taken on the basis of any material in this document. The Commonwealth of Australia, Rural Industries Research and Development Corporation, the authors or contributors do not assume liability of any kind whatsoever resulting from any person's use or reliance upon the content of this document. This publication is copyright. However, RIRDC encourages wide dissemination of its research, providing the Corporation is clearly acknowledged. For any other enquiries concerning reproduction, contact the Publications Manager on phone 02 6272 3186. Researcher Contact Details Prof. T. V. Riley University of Western Australia School of Biomedical and Chemical Sciences Microbiology (M502) 35 Stirling Hwy CRAWLEY WA 6009 Phone: (08) 9346 3690 Fax: (08) 9346 2912 Email: [email protected] In submitting this report, the researcher has agreed to RIRDC publishing this material in its edited form. -
Chemical %Concentration CAS
Sebozole Shampoo Page 1of 5 Sebozole Shampoo SAFETY DATA SHEET (1) IDENTIFICATION Name: Sebozole Shampoo Use: veterinary skin care Supplier: Vetoquinol USA (Tomlyn Products) 4250 N. Sylvania Ave Fort Worth, TX 76137 Tel: ( 817)529-7500 Fax: (817)529-7506 (2) HAZARD(S) IDENTIFICATION Hazard Classification: Non Hazardous as defined by 29CFR Part 1910.1200 (3) COMPOSITION/INFORMATION ON INGREDIENTS Common Name: Sebozole Shampoo Composition: A blend of proprietary ingredients which make a veterinary dermatologic care product. Chemical %Concentration CAS Sodium Thiosulfate 3.13 10102-17-7 Miconazole Nitrate 2.0 22916-47-8 Salicylic Acid 2.0 69-72-7 Chloroxylenol 1.0 88-04-0 Sodium Olefin Sulfonate 25 6843-57-6 PEG 150 Pentaerythrityl Tetratstearate 5 130249-48-8 Lauramide DEA 5 92680-75-6 Propylene Glycol 5 57-55-6 Ultrez 21 1 9003-39-8 Sodium Hydroxide 1 1310-73-2 Fragrance 0.5 Kathon CG 0.1 6118-96-6 FD&C yellow #5 0.0013 84842-94-4 FD&C Blue #1 0.0013 3844-45-9 Purified Water 49 7732-18-5 Sebozole Shampoo Page 2 of 5 (4) First Aid Measures Ingestion • In case of ingestion call a physician and poison control. EYE • If product enters eye, rinse thouroughly with cool fresh water for 10 to 15 minutes. If irritation persists, seek medical attention. • a burning sensation, excessive tears, sensitivity to light, swelling and redness of the conjunctiva and increasedblinking. • Limited evidence or practical experience suggests, that the material may cause eye irritation in a substantial number of individuals.Prolonged eye contact may cause inflammation characterized by a redness of the conjunctiva (similar to windburn SKIN • none INHALED • None (5) FIRE-FIGHTING MEASURES Suitable Extinguisher: FOAM, DRY POWDER, WATER, CO2 Special Precautions: None Special Protective Equipment: None (6) ACCIDENTAL RELEASE PROCEDURES Personal Precautions: None. -
Stanford Storage Groups
STANFORD STORAGE Ethylene Glycol G Sigmacote L GROUPS Ficoll G Silver Nitrate E Formaldehyde w/ methanol L Sodium Acetate G CHEMICAL GRP Formaldehyde <37%, G Sodium Azide X 1-Butanol or 2- L 20% NBF Formalin Sodium Bicarbonate G 1-Propanol L Formamide L Sodium Bisulfite G 2-Mercaptoethanol L Formic Acid D Sodium Borate (borax) G Acetic Acid, Glacial D Glutaraldehyde D Sodium Carbonate G Acetic Anhydride L Glycerol L Sodium Chloride G Acetone L Glycine G Sodium Citrate, Dihydrate G Acrolein L Guanidine Hydrochloride G Sodium Hydroxide C Acrylamide G Guanidine Thiocyanate C Sodium Hypochlorite E Agarose G Gluconic Acid G (Bleach) Ammonium Acetate G HEPES D Sodium Per(anything) E Ammonium Chloride G Hydrochloric Acid F Sodium Phosphate G Ammonium Hydroxide C Hydrogen Peroxide, 30% E Sodium Sulfide, Anhydrous X Ammonium Molybdate G Imidazole A Sodium Thiosulfate G Ammonium Nitrate E Iodine E Succinic Acid G Ammonium Persulfate E Isoamyl or isobutyl alcohol L Sucrose G Ammonium Sulfate G Isopropanol L Sulfuric Acid F Ammonium Sulfide L Magnesium Chloride G Tannic Acid D Ascorbic Acid G Magnesium Sulfate G TEMED A BIS & BIS-Acrylamide G Maleic Acid D TES free acid G BIS TRIS A Mercaptoethanol L Tetracycline G Boric Acid G MES G Trichloroacetic Acid D Calcium Chloride G Methanol L Tricine G Cesium Chloride G N-Methyl-2-Pyrrolidone A Toluene L Cesium Fluoride F Mineral Oil L Triethanolamine A Cesium Hydroxide C Nitric Acid E TRIS, base A CHAPS G Oxalic Acid D TRIS Hydrochloride G Chloroform G Paraformaldehyde A Triton X-100 G Chromerge E Perchloric -
Potassium Iodate, 0.00564N (0.00094M) Safety Data Sheet According to Federal Register / Vol
Potassium Iodate, 0.00564N (0.00094M) Safety Data Sheet according to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations Date of issue: 04/15/2015 Revision date: 02/08/2018 Supersedes: 02/08/2018 Version: 1.1 SECTION 1: Identification 1.1. Identification Product form : Mixtures Product name : Potassium Iodate, 0.00564N (0.00094M) Product code : LC19600 1.2. Recommended use and restrictions on use Use of the substance/mixture : For laboratory and manufacturing use only. Recommended use : Laboratory chemicals Restrictions on use : Not for food, drug or household use 1.3. Supplier LabChem Inc Jackson's Pointe Commerce Park Building 1000, 1010 Jackson's Pointe Court Zelienople, PA 16063 - USA T 412-826-5230 - F 724-473-0647 [email protected] - www.labchem.com 1.4. Emergency telephone number Emergency number : CHEMTREC: 1-800-424-9300 or 011-703-527-3887 SECTION 2: Hazard(s) identification 2.1. Classification of the substance or mixture GHS-US classification Not classified 2.2. GHS Label elements, including precautionary statements Not classified as a hazardous chemical. Other hazards not contributing to the : None under normal conditions. classification 2.4. Unknown acute toxicity (GHS US) Not applicable SECTION 3: Composition/Information on ingredients 3.1. Substances Not applicable 3.2. Mixtures Name Product identifier % GHS -US classification Water (CAS-No.) 7732-18-5 99.98 Not classified Potassium Iodate (CAS-No.) 7758-05-6 0.02 Ox. Sol. 3, H272 Full text of hazard classes and H-statements : see section 16 SECTION 4: First-aid measures 4.1. -
TITRATIONS with POTASSIUM IODATE Potassium Iodate Is a Fairly
TITRATIONS WITH POTASSIUM IODATE Potassium iodate is a fairly strong oxidizing agent that may be used in the assay of a number of pharmaceutical substances, for instance : benzalkonium chloride, cetrimide, hydralazine hydrochloride, potassium iodide, phenylhydrazine hydrochloride, semicarbazide hydrochloride and the like. Under appropriate experimental parameters the iodate reacts quantitatively with both iodides and iodine. It is, however, interesting to observe here that the iodate titrations may be carried out effectively in the presence of saturated organic acids, alcohol and a host of other organic substances. The oxidation-reduction methods with potassium iodate invariably based on the formation of iodine monochloride (ICl) in a medium of strong hydrochloric acid solution. Preparation of 0.05 M Potassium Iodate Potassium iodate is dried to a constant weight at 110°C to make it completely free from moisture and then brought to room temperature in a desiccator. It is pertinent to mention here that KIO3 is a very stable salt and may be obtained in a very pure form. Therefore, it is possible to prepare the standard solutions of KIO3 by dissolving the calculated weight of the salt in water and diluting the same to an approximate volume. Since, the normality of iodate solution varies significantly depending on the nature of the reaction, therefore, in usual practice standard iodate solutions of known molarity are used. The reduction of potassium iodate to iodide is usually not feasible in a direct titrimetric method (unlike the reduction of potassium bromate to bromide) and hence, has no viable application in the official procedures ...........................(a) In this type of reaction, 1 mol of KIO3 is 6 equivalent and a 0.05 M solution would be 0.3 N. -
Consideration of Mandatory Fortification with Iodine for Australia and New Zealand Food Technology Report
CONSIDERATION OF MANDATORY FORTIFICATION WITH IODINE FOR AUSTRALIA AND NEW ZEALAND FOOD TECHNOLOGY REPORT December 2007 1 Introduction Food Standards Australia New Zealand is considering mandatory fortification of the food supply in Australia and New Zealand with iodine. Generally, the addition of iodine to foods is technologically feasible. However, in some instances the addition of iodine can lead to quality changes in food products such as appearance, taste, odour, texture and shelf life. These changes will depend on the chemical form of iodine used as a fortificant, the chemistry of the food that is being fortified, the food processes involved in manufacture and possible processing interactions that could occur during distribution and storage. Many foods have been fortified with iodine and the potassium salts of iodine compounds have been used as the preferred form. 2 Forms of Iodine Iodine is normally introduced, or supplemented, as the iodide or iodate of potassium, calcium or sodium. The following table lists different chemical forms of iodine along with their important physical properties. Table 1: Physical Properties of Iodine and its Compounds Name Chemical Formula % Iodine Solubility in water (g/L) 0°C 20°C 30°C 40°C 60°C Iodine I2 100 - - 0.3 0.4 0.6 Calcium iodide CaI2 86.5 646 676 690 708 740 Calcium iodate Ca(IO3)2.6H2O 65.0 - 1.0 4.2 6.1 13.6 Potassium iodide KI 76.5 1280 1440 1520 1600 1760 Potassium iodate KIO3 59.5 47.3 81.3 117 128 185 Sodium iodide NaI.2H20 85.0 1590 1790 1900 2050 2570 Sodium iodate NaIO3 64.0 - 25.0 90.0 150 210 Adapted from Mannar and Dunn (1995) 2.1 Potassium Iodide Potassium iodide (KI) is highly soluble in water. -
Potassium Iodate
374 Potassium Iodate COHPONENTS: EVALUATOR: (1) Potassium iodate; KI03; [7758-05-6] H. Miyamoto Niigata University Niigata, Japan (2) Water; H20; [7732-18-5] and Mark Salomon US Army ET & DL Fort Monmouth, NJ, USA June, 1986 CRITICAL EVALUATION: THE BINARY SYSTEM Solubility data for KI03 in pure water have been reported in 30 publications (1-28, 35, 36). A summary of the solubility data over the temperature range 273-373 K is given in Table 1. Note that the data from references (15, 16, 20 and 31) have been compiled in the LiI03 chapter, and the data in reference (3) have been compiled in the NaI03 chapter. With the exception of the high temperature study of Benrath et al. (7) which employed the synthetic method, all other studies are based on the isothermal method. From Table 1 it is seen that a number of authors reported identical solubilities in more than one publication, and the evaluators have therefore treated these results as one independent measurement. Thus, at 298.2 K, the data in (3, 8, 10) have been treated as one independent solubility value as have the data reported in (17, 19, 23), and at 323.2 K in (18, 21, 26). Most authors reported the solid phase over the temperature range of 278-323 K as the anhydrous salt, and although Breusov et al. (11) and Benrath et al. (7) did not report the nature of the solid phases over the temperature range of 273-573 K, it probably is the anhydrous salt in all cases. In fitting the solubility data to the two smoothing equations, a number of data points were rejected as the differences in smoothed (calculated) solubilities differed from the experi mental values by more than 20 (where a is the standard error of estimate).